Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552117 | 0.91 | PTGDR2 (0.71) | PTGDR2RAB9ANPC1MEN1GAA | |
| SCHEMBL1996701 | 0.88 | PTGDR2 (0.55) | PTGDR2RAB9ANPC1MAPT | |
| SCHEMBL1994973 | 0.87 | PTGDR2 (0.68) | PTGDR2RAB9ANPC1MEN1GAA | |
| SCHEMBL1994972 | 0.87 | PTGDR2 (0.68) | PTGDR2RAB9ANPC1MEN1GAA | |
| SCHEMBL5553189 | 0.83 | PTGDR2 (0.59) | PTGDR2KMT2AMAPTHPGDHTT | |
| SCHEMBL1994430 | 0.81 | PTGDR2 (1.00) | PTGDR2RAB9ANPC1MAPT | |
| SCHEMBL1993750 | 0.80 | PTGDR2 (1.00) | PTGDR2RAB9ANPC1MAPTHTT | |
| SCHEMBL1995200 | 0.78 | PTGDR2 (0.76) | PTGDR2RAB9ANPC1MAPTHPGD | |
| SCHEMBL1994664 | 0.77 | PTGDR2 (0.53) | PTGDR2RAB9ANPC1MAPTHPGD | |
| SCHEMBL2000166 | 0.77 | PTGDR2 (0.59) | PTGDR2RAB9ANPC1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269763-A1 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-11-03 | — | — | US | disclosed |
| US-8022063-B2 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-09-20 | — | — | US | disclosed |
| EP-2336113-A1 | CRTH2 Receptor Ligands for Medical Use | 7TM Pharma A/S (DK) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269763-A1 | CRTH2 receptor ligands for medicinal uses | HRH1, HRH2, HRH4 | PTGDR2 61/4885RAB9A 2089/4885NPC1 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.